Targeted radioactive therapy for prostate cancer

Affiliations

¹ Nuclear Medicine Department, Bordeaux University Hospital, 33604 Pessac, France. Electronic address: elif.hindie@chu-bordeaux.fr.
² Nuclear Medicine Department, Bordeaux University Hospital, 33604 Pessac, France.
³ CELIA, University of Bordeaux, Talence, France.

Comment

Elif Hindié et al. Lancet. 2021.

. 2021 Aug 7;398(10299):487.

doi: 10.1016/S0140-6736(21)01045-X.

¹ Nuclear Medicine Department, Bordeaux University Hospital, 33604 Pessac, France. Electronic address: elif.hindie@chu-bordeaux.fr.
² Nuclear Medicine Department, Bordeaux University Hospital, 33604 Pessac, France.
³ CELIA, University of Bordeaux, Talence, France.

No abstract available

Conflict of interest statement

We declare no competing interests.

Targeted radioactive therapy for prostate cancer - Authors' reply.
Hofman MS, Sandhu S, Francis RJ, Davis ID, Emmett L. Hofman MS, et al. Lancet. 2021 Aug 7;398(10299):488. doi: 10.1016/S0140-6736(21)01060-6. Lancet. 2021. PMID: 34364519 No abstract available.

[¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.